Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia

• Status: Completed
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will further analyze the use of ceftaroline for CABP and compare its potential to eradicate bacterial pathogens to standard fluoroquinolone therapy. The enhanced spectrum of ceftaroline compared to levofloxacin may be further highlighted from this investigation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gary E. Stein, Pharm.D.
• Collaborator: Forest Laboratories
• Treatments: Ceftaroline fosamil; Levofloxacin; Ofloxacin

Criteria

Inclusion Criteria:

• non-pregnant adults (≥ 18 years old) with suspected CABP admitted to the hospital for parenteral antibiotic therapy.

• All patients will have a creatinine clearance (CrCl) >50 ml/min.

Exclusion Criteria:

• pregnant or nursing patients,

• allergy to penicillin/cephalosporin antibiotics,

• allergy to fluoroquinolones,

• renal or hepatic failure, or have received an antimicrobial in past 96h.

• Patients who require antibiotics other than the study drugs will also be excluded.